$SCYX News

SCYNEXIS Starts Phase 1 Trial Of SCY-770 Activator Of Two Dosing Regimens

SCYNEXIS Announces One-for-Eight Reverse Stock Split

SCYNEXIS Announces 1-For-8 Reverse Stock Split, Effective May 29

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

SCYNEXIS Q1 EPS $(0.42) Misses $(0.12) Estimate

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SCYNEXIS Announces Prospectus Of 87M Shares By Selling Stockholders

SCYNEXIS INC (NASDAQ:SCYX) Combines Minervini Trend Template with High-Growth Momentum Fundamentals

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics - Slideshow

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease

SCYNEXIS Announces $40.0 Million Private Placement

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SCYNEXIS Announces $40M Private Placement, Warrants May Add $52M To Proceeds

SCYNEXIS Agrees With Poxel To Acquire PXL-770; $8M Upfront, Up To $188M Milestones

SCYNEXIS Says On March 15, 2026 Co Received FDA Orphan Drug Designation For Brexafemme (Triterpenoid Antifungal) For Treatment Of Invasive Candidiasis

SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy

Scynexis: Q4 Earnings Snapshot

SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

SCYNEXIS Q4 Earnings Assessment